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Abstract
Background: Early identification of patients with Crohn’s disease (CD) at risk of subsequent 
complications is essential for adapting the treatment strategy. We aimed to develop a prediction 
model including clinical and serological markers for assessing the probability of developing 
advanced disease in a prospective referral CD cohort.
Methods: Two hundred and seventy-one consecutive CD patients (42.4% males, median follow-up 
108 months) were included and followed up prospectively. Anti-Saccharomyces cerevisiae antibodies 
(ASCA IgA/IgG) were determined by enzyme-linked immunosorbent assay. The final analysis was 
limited to patients with inflammatory disease behaviour at diagnosis. The final definition of advanced 
disease outcome was having intestinal resection or disease behaviour progression.
Results: Antibody (ASCA IgA and/or IgG) status, disease location and need for early azathioprine 
were included in a 3-, 5- and 7-year prediction matrix. The probability of advanced disease after 
5 years varied from 6.2 to 55% depending on the combination of predictors. Similar findings were 
obtained in Kaplan–Meier analysis; the combination of ASCA, location and early use of azathioprine 
was associated with the probability of developing advanced disease (p < 0.001, log rank test).
Conclusions: Our prediction models identified substantial differences in the probability of 
developing advanced disease in the early disease course of CD. Markers identified in this referral 
cohort were different from those previously published in a population-based cohort, suggesting 
that different prediction models should be used in the referral setting.
Keywords:  Serological antibodies; ASCA; Crohn’s disease; disease progression; referral cohort; azathioprine
1. Introduction
Crohn’s disease (CD) is a multifactorial chronic inflammatory dis-
ease of the gastrointestinal tract. It runs a variable disease course, yet 
the majority of patients eventually develop penetrating or stricturing 
complications leading to repeated surgery and disability.1
Studies on the natural history of CD provide important data 
on its course and may help to identify clinical predictors of disease 
progression. Some years ago, Peyrin-Biroulet et al.2 published a sys-
tematic review of the natural history of CD in population-based 
cohorts and concluded that available data did not suggest a signifi-
cant change in disease course, with approximately half of patients 
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requiring surgery within 10 years after diagnosis. Furthermore, the 
authors stated that the impact of changes in monitoring and treat-
ment paradigms with increased and earlier use of immunosuppres-
sants and biological agents on the natural history of the disease was 
poorly understood.
Interestingly, an increasing proportion of patients were diagnosed 
with uncomplicated disease behaviour in recent population-based 
cohorts; e.g. in a study from New Zealand >70% of CD patients 
had inflammatory disease at diagnosis, while only 23 and 40% of 
these progressed to complicated disease 5 and 10 years after diag-
nosis, respectively.3 Similarly, the rate of initial inflammatory disease 
behaviour was as high as 68 and 75% in CD patients from Western 
and Eastern Europe, respectively, in the most recent EpiCom study,4 
with only 10% of all patients presenting with perianal involvement.
Therefore, early stratification of patients became of the utmost 
importance to avoid negative outcomes and considerable emphasis 
has been placed in recent years on the determination of important 
predictive factors. In one of the early approaches, an initial need for 
steroid use, age below 40 years and the presence of perianal disease 
were associated with the development of disabling disease in the 
landmark paper by Beaugerie et al.5 However, the definition of disa-
bling outcome was complex and included the need to start immu-
nosuppressives. Multiple studies reported a more rapid progression 
towards complicated disease in CD patients with small bowel or per-
ianal disease.3,6 In another Belgian study, besides perianal lesions, the 
early need for steroids and ileocolonic location, but not age below 
40 years, were identified as predictive markers for the development 
of disabling disease (according to the predefined criteria) at 5 years.7 
In addition, according to available data paediatric-onset CD runs a 
more aggressive course, with more extensive disease location, more 
upper gastrointestinal involvement, more active disease, growth fail-
ure and the need for more aggressive medical therapy in predomi-
nantly referral centre studies,8–10 with some exceptions.11
Recently, the IBSEN group12 has developed a population-based 
risk assessment model based on complex evaluation of clinical (age at 
onset, location and early steroid requirement) and serological (anti-
Saccharomyces cerevisiae antibody [ASCA] positivity) variables that 
was able to predict the risk of disease outcome 5 and 10 years after 
diagnosis. However, similarly to the previous French5 approach, the 
need for immunosuppressants was defined as an adverse outcome. In 
contrast, in an earlier study by our group, early aggressive immuno-
suppressive therapy was associated with a reduction in surgical rates 
in a population-based study13 from Hungary, even after fitting the 
model on propensity scores. Almost certainly, future complex predic-
tion models should assess the value of an early aggressive treatment 
strategy as a possible predictor of disease progression.
Early identification of CD patients at risk of subsequent compli-
cations is essential for adapting the treatment strategy in everyday 
clinical practice, especially in CD patients followed up at referral 
inflammatory bowel disease (IBD) centres. Therefore, the aim of the 
present study was to develop a prediction model including clinical 
and serological markers for assessing the probability of developing 
advanced disease during medium-term follow-up in a prospective 
referral CD cohort.
2. Methods
2.1. Patient population
A total of 271 well-characterized, unrelated, consecutive CD patients 
with a complete clinical follow-up {male/female, 120/140; median 
age at presentation, 25  years (interquartile range [IQR]), 19–33} 
seen in one tertiary IBD referral centre in Hungary (Department 
of Gastroenterology, Institute of Internal Medicine, University of 
Debrecen) were included between 1 January 2005 and 1 June 2010 
and were followed up until 1 October 2013. Blood samples and 
detailed clinical phenotypes were captured at inclusion.
The clinical characteristics of the patients at diagnosis are pre-
sented in Table 1. Diagnosis of IBD was based on the Lennard-Jones 
criteria.14 The disease phenotype (age at onset, duration, location 
and behaviour) was determined according to the Montreal classifica-
tion.15 Blood samples and detailed clinical phenotypes were captured 
at inclusion. Clinical data were determined by thorough review of 
patients’ medical records, which had been collected in a uniform for-
mat. Medical records that documented the disease phenotype, pres-
ence of extraintestinal manifestations (e.g. arthritis [peripheral and 
axial]; ocular manifestations [conjunctivitis, uveitis, iridocyclitis]; skin 
lesions [erythema nodosum, pyoderma gangrenosum]; and hepatic 
manifestations [primary sclerosing cholangitis]), frequency of flare-
ups (frequent flare-up was >1 clinical relapse/year),16 medication use 
(e.g. steroid, immunosuppressive and/or biological use at any time), 
need for surgery (resections), the presence of familial IBD, smoking 
habits and perianal involvement were retrospectively analysed for the 
period prior to the prospective follow-up and prospectively thereafter.
In Hungary, a follow-up visit is usually scheduled for every 
6 months at a specialized gastroenterology centre (the actual interval 
varies between 3 and 6 months). In addition, a harmonized, manda-
tory, tight monitoring strategy is requested and regularly controlled 
by the National Health Fund (OEP) in anti-tumour necrosis factor 
(TNF)-exposed patients, including Crohn’s disease activity index-
perianal disease activity index (CDAI-PDAI) assessment, labora-
tory evaluation (including C-reactive protein [CRP]) at least every 
3 months and endoscopy/imaging at least every 12 months. The start 
of immunosuppressive or anti-TNF treatment was indicated by the 
same three IBD specialists throughout the study period by using the 
European Crohn’s and Colitis Organisation (ECCO) guidelines, the 
centre’s treatment policy and prescription regulations. Follow-up 
was terminated if there was no further record available. Median 
follow-up from diagnosis was 108 months (IQR, 65–178).
2.2. Definitions of advanced disease
Two definitions were used for advanced disease: (1) having intestinal 
resection or progression in disease behaviour; and (2) having intes-
tinal resection, progression in disease behaviour or need for thio-
purines (IBSEN definition). Early need for azathioprine (AZA) was 
defined as need of AZA within 3 years from diagnosis.
2.3. Serological analysis
Blood samples were obtained at enrolment from each patient and 
were frozen at –80°C until testing. All serological assays were 
Table 1. Clinical characteristics of the referral cohort with Crohn’s 
disease (CD).
CD patients (n = 271)
Males/females 42.4/47.6%
Median follow-up (IQR), months 108 (65–178)
Inflammatory behaviour at diagnosis 79.7%
Ileocolonic disease at diagnosis 45.0%
Complicated disease behaviour at last follow-up 52.0%
At least one resective surgery at last follow-up 41.1%
Total steroid exposure 88.2%
Total azathioprine exposure 73.8%
Total anti-TNF exposure 41.7%
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performed in a blinded fashion without prior knowledge of the 
patient’s diagnosis or other clinical information. Sampling was done 
at early stages of the disease (duration of disease less than 2 years) 
in 40.2% of the patients the and after a disease duration of more 
than 2 years of in 59.8% of patients. The overall disease duration 
(median) at sampling was 3 years (IQR 0–8 years).
2.4. Detection of antimicrobial antibodies
The presence of ASCA IgA and ASCA IgG in serum was determined 
by enzyme-linked immunosorbent assay (ELISA) (QUANTA Lite™, 
Inova Diagnostics, San Diego, CA) according to the manufacturers’ 
instructions. The results are presented as arbitrary units, and values 
above the cut-off of 25 units were considered positive. The results 
were documented in absolute values and in frequency of positivity.
All the serological assays were performed in a blinded fashion 
without prior knowledge of the patient’s diagnosis or other clinical 
information.
2.5. Ethical considerations
The regional and national committee [DEOEC RKEB/IKEB 3515-
2011, 3880/2012/EKU (59/PI/2012)] for research ethics approved 
the study protocol. Each patient was informed of the nature of the 
study and signed an informed consent form.
2.6. Statistical analysis
Continuous variables were summarized as median (IQR) accord-
ing to their homogeneity. The predictive potential of the different 
models for predicting advanced outcome according to the two 
pre-set definitions were tested both by cross-sectional analysis 
after pre-set time-points at 3, 5 and 7  years after the diagno-
sis and in time-dependent models. We developed two different 
models. In the first model we replicated a matrix model with the 
original variables and outcome definition reported by the IBSEN 
group12 in our referral cohort, both after the pre-set time-points 
and in the time-dependent model. However, because of the limited 
number of cases we limited the final model to the combination 
of three variables. This was based on the results of univariate χ2 
tests, in which age at diagnosis was not significant. In the sec-
ond step, since the predictive potential was improved by grouping 
the location as colon only vs ileal involvement (padvanced disease for L2 vs 
other = 0.002), we repeated the testing after changing the location 
grouping. In addition, our group has shown that early AZA ther-
apy is a treatment decision rather than a negative outcome and 
may predict surgical outcome in the population-based setting13 
and early AZA need in the present study was associated with 
advanced disease in every model. Therefore, in the third step we 
developed a new model and analysed the outcomes after replac-
ing early steroid requirement with early AZA requirement and 
used a modified advanced disease definition (excluding the need 
for AZA). In addition, the association between possible risk fac-
tors and the modified advanced 5-year outcome definition were 
assessed by both univariate and multivariate logistic regression 
testing. Variables with p < 0.2 were selected for multiple testing.17 
In addition, Kaplan–Meier survival curves were plotted to ana-
lyse the association between the combination of clinical variables, 
serological antibodies and complicated disease outcomes during 
follow-up with the log rank test. A  two-sided probability value 
<0.05 was considered to be statistically significant. For statistical 
analysis, GraphPadPrism 6 (San Diego, CA) and SPSS 20.0 (SPSS 
Inc., Chicago, IL) programs were used.
3. Results
3.1. Clinical characteristics
At diagnosis, 79.7% of the CD patients had inflammatory behaviour 
and 45% had ileocolonic disease (Table 1). Disease progression dur-
ing follow-up was significant, with 52% of the patients progressing 
to complicated disease behaviour and 41.1% of the patients hav-
ing at least one resective surgery at the last follow-up. Total expo-
sures to steroids, AZA and anti-TNFs were 88.2, 73.8 and 41.7%, 
respectively.
3.2. Predicting advanced disease during follow-up 
in referral CD patients with non-stricturing and  
non-penetrating disease behaviour at diagnosis
The association between clinical and serological variables and 
advanced outcome at 3, 5 and 7 years by either the original defini-
tion or the modified definition is summarized in Table 2. Location 
(colon vs ileal involvement), early AZA need and ASCA positivity 
were identified as independent predictors of advanced outcome. The 
original model, including ASCA (IgA and/or IgG), disease location 
and early need for steroids but not age at onset, was of low dis-
criminative potential to predict advanced outcome in this referral 
CD cohort at 5 years if the original definition was used (Table 3). In 
addition, a lack of separation among the groups was observed in the 
time-dependent model (Figure 1, not significant for ASCA positive vs 
negative subgroups).
The predictive potential was not much better if the need for AZA 
was excluded from the advanced disease definition (data not shown).
The predictive potential of the model was not much better after 
changing the location grouping both with the original definition 
(Table 4) and with the modified definition of advanced outcome after 
excluding need for AZA from the advanced outcome definition (data 
not shown).
The combination of ASCA (IgA and IgG) status, disease location 
and need for early AZA was associated with advanced outcome by 
using the modified definition of advanced disease (need for surgery 
and disease behaviour change). The probabilities of advanced disease 
5 years after diagnosis varied from 6.2 to 55% depending on the 
combination of predictors (Table 5). The 3- and 7-year ASCA-based 
model resulted in probabilities of advanced disease ranging from 
0 to 45.5% and from 11.1 to 64.7%, respectively. Similar findings 
were obtained by Kaplan–Meier analysis, in which the combination 
of ASCA, location and early AZA was associated with the probabil-
ity of developing advanced disease (plogrank < 0.001, Figure 2).
4. Discussion
The present study has shown that the disease course may be pre-
dicted in referral CD patients by the use of a complex model includ-
ing disease phenotype and serological and treatment variables. We 
have also confirmed that different models are necessary for the pre-
diction of disease outcomes in referral CD cohorts with different 
predictors compared with the population-based setting.
2 The risk factors – location, ASCA, early steroid requirement 
and early azathioprine therapy – identified for developing disease 
complication (in the present study the final definition was a change 
in disease behaviour or surgery) in patients with initial uncompli-
cated disease were in line with factors identified in previous popu-
lation-based3,12,13 or referral cohort5–7,18 studies. Of note, however, 
there is a significant variance in the definition of adverse outcome in 
the published literature. In the French study,5 performed in a tertiary 
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referral centre in 1123 patients, adverse outcome was defined as ful-
filling at least one of the following criteria within the first 5 years 
after the diagnosis: the need for more than two steroid courses or 
steroid dependency; the need for immunosuppressive treatment; 
disabling chronic symptoms; hospitalization; or surgery. Using this 
definition, three risk factors at diagnosis were found to be inde-
pendently associated with a disabling 5-year course of disease: age 
<40 years; presence of perianal disease; and requirement for steroids. 
However, these factors differ clearly in clinical importance and there 
is little doubt that the start of immunosuppressive therapy repre-
sents a treatment strategy decision rather than a negative outcome. 
However, the discriminative potential of the model was low, as the 
chance for disabling outcome in this referral CD cohort was approx-
imately 90% in the first 5 years of the disease.
3 In a Belgian referral cohort study, ileocolonic location, peri-
anal lesions and the need for steroids for the first flare, but not age 
below 40 years, were identified as predictive markers for developing 
disabling disease at 5 years.7 In the same study, stricturing behaviour 
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Figure 1. Probability of developing advanced disease outcome according to the original definition in referral Crohn’s disease patients with non-stricturing and 
non-penetrating disease behaviour (B1) at diagnosis.
Table 4. Risk matrix showing advanced 5-year outcome according to the original definition1 in referral Crohn’s disease patients with non-
stricturing and non-penetrating disease behaviour (B1) at diagnosis after changing the location grouping.
ASCA (either IgA or IgG) Early steroid requirement2 Only colon location at diagnosis (L2 + L3) Ileal location at diagnosis (L1 + L4)
ASCA positive Yes 58.3% 80.0%
No 63.6% 58.3%
ASCA negative Yes 73.7% 70.4%
No 22.6% 26.1%
1Having intestinal resection, progression in disease behaviour, or need for thiopurines (IBSEN definition).
2Within 30 days from diagnosis.
ASCA, anti-Saccharomyces cerevisiae antibodies.
Table 3. Risk matrix showing advanced 5-year outcome according to the original definition1 in referral Crohn’s disease patients with non-
stricturing and non-penetrating disease behaviour (B1) at diagnosis.
ASCA (IgA and/or IgG) Early steroid requirement2 Colon location at diagnosis (L2 + L3) Ileal or upper gastrointestinal tract location (L1 + L4)
ASCA positive Yes 72.5% 66.7%
No 50.0% 53.3%
ASCA negative Yes 69.6% 75.0%
No 16.7% 30.0%
1Having intestinal resection, progression in disease behaviour or need for thiopurines (IBSEN definition).
2Within 30 days from diagnosis.
ASCA, anti-Saccharomyces cerevisiae antibodies.
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and weight loss at diagnosis were independently associated with the 
time to development of severe disease. However, the definition of 
adverse outcome was different. The authors focused on more objec-
tive factors and the definition included the presence of at least one 
of the following criteria: the development of complex perianal dis-
ease; any colonic resection; two or more small-bowel resections (or 
a single small bowel resection more than 50 cm in length); or the 
construction of a definite stoma. Similarly, perianal disease, small 
bowel disease, smoking, prior steroid use, early AZA or AZA/bio-
logical therapy were all predictors of disease behaviour change in 
our previous referral CD cohort study.6 Furthermore, progression 
towards complicated disease was also more rapid in those with small 
bowel compared with colonic disease (p < 0.001) in a New Zealand 
cohort,3 and perianal disease was a significant predictor of change 
in CD behaviour (hazard ratio 1.62, p < 0.001). Thus, patients with 
small bowel involvement should be observed especially closely.
4 In addition, biomarkers, including serological markers, espe-
cially ASCA, were linked to complicated disease behaviour and 
CD-related surgery in previous referral CD cohorts and in a meta-
analysis.18–20 Furthermore, in CD, but not in ulcerative colitis, they 
have also been associated with prediction of aggressive disease 
phenotype and faster progression towards complicated disease and 
the need for surgery.21
5 Finally, the treatment strategy has also changed in the last 
decade. Monitoring has become tighter and immunomodulator 
therapy has been introduced earlier. Relatively recent population-
based studies in Wales and Hungary 13,22 reported that early AZA 
use may be associated with reduced need for resective surgery and 
a delay in the time to first operation in a population-based CD 
cohort after matching for propensity scores in the later study. Two 
recent controlled trials from the French and Spanish IBD groups23,24 
investigating the clinical benefit of systematic early introduction of 
AZA failed to show a short-term benefit for symptomatic relapse 
and clinical remission rates even though the need for perianal sur-
gery was lower (4 vs 18%, p = 0.036) in the study by the GETAID 
group.23 Thus, whether azathioprine has the potential for disease 
modification in early CD remains controversial. Interestingly, in 
the present referral cohort, early AZA use was not preventive of 
advanced outcome in initially B1 patients. Of note, however, this 
reflects, at least partly, the differences in the cohort setting, and 
a high percentage of patients in the present referral cohort were 
treated with anti-TNFs.
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Figure 2. Probability of developing advanced disease outcome according to the modified definition in the referral Crohn’s disease cohort in patients with non-
stricturing and non-penetrating disease behaviour (B1) at diagnosis.
Table 5. Association between anti-Saccharomyces cerevisiae antibody (ASCA) IgA and IgG positivity, disease location and need for early 
azathioprine (AZA) with the probability of developing advanced disease outcome at 5 years according to the modified definition1 after 
diagnosis in referral Crohn’s disease patients with non-stricturing and non-penetrating (B1) disease behaviour at diagnosis.
ASCA (IgA and IgG) Early AZA requirement2 Only colon location at diagnosis (L2) Ileal location at diagnosis (L1, L3, L4)
ASCA positive Yes 50.0% 55.0%
No 30.8% 29.0%
ASCA negative Yes 11.1% 22.2%
No 6.2% 18.8%
1Need for surgery and disease behaviour change.
2Need for AZA within 3 years from diagnosis.
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In the present study we wanted to exclude patients with already 
complicated disease and focused on identifying possible risk factors 
for advanced disease in the subgroup of patients with non-compli-
cated disease behaviour (B1) at diagnosis. In previous studies, the 
probability of developing complications in CD was reported to be 
highest during the first years after diagnosis.3,5,6 Furthermore, there 
is a window of opportunity in CD and clinical outcomes were bet-
ter with early aggressive therapy in the first years of the disease.25,26 
Therefore, we focused on the first 3–7  years of the disease in the 
prediction models. During this period, 30.4, 42.8 and 52% of B1 
patients developed advanced disease at 3, 5 and 7 years, respectively, 
according to the modified definition (disease behaviour change or 
need for resective surgery). Although a direct comparison with the 
IBSEN cohort12 should be interpreted with caution, a much lower 
proportion of the patients (approximately 36%) developed an 
advanced outcome after 5 years according to the original definition 
including the need for immunosuppressives. The rate of advanced 
disease according to this definition was 64.5% at 5  years in this 
referral cohort, which reflects at least partly the different cohort set-
ting and inherent higher disease progression rates in a referral set-
ting. Of note, the probability of developing advanced disease during 
the first 5 years using the modified criteria ranged from 6.2 to 55.5% 
in the final model depending on the number of positive risk factors, 
demonstrating a good discriminative potential of the tool to assess 
the future risk of developing advanced disease in a given patient 
based on a given risk factor profile shortly after diagnosis.
The authors are aware of possible limitations of the present 
study. Serological markers were not measured in each patient at the 
time of diagnosis, although the stability of these markers has been 
previously demonstrated.27 Patient management in CD has changed 
significantly in the last decade, including tight monitoring and 
quicker access to imaging (e.g. availability of computed tomogra-
phy and magnetic resonance imaging), increased and earlier access 
to anti-TNFs and also surgery techniques, especially in referral 
centres, and this could have potentially affected the probability of 
developing advanced outcomes and surgery rates in CD. Therefore, 
the results of our study may not be generalized to patient cohorts 
outside IBD centres and with more limited access to biological 
therapies and less stringent patient monitoring. In contrast, the 
strengths of the study include tight uniform patient monitoring and 
the use of a more straightforward definition of advanced disease 
outcome that includes only high-impact clinical scenarios. In addi-
tion, access to biological therapy in Hungary is currently one of the 
best in Middle-Eastern Europe, with more than 2500 IBD patients 
on anti-TNF therapy, being approximately 9% of CD patients.28 
A harmonized, mandatory, tight monitoring strategy is requested 
and regularly controlled by the National Health Fund (OEP) in 
anti-TNF-exposed patients, including CDAI-PDAI assessment, 
laboratory evaluation (including CRP) at least every 3 months and 
endoscopy/imaging at least every 12  months. Furthermore, bio-
logical therapy is centralized in Hungary to 16 high-volume IBD 
centres that serve as tertiary referral centres for IBD, and expo-
sure to anti-TNFs in these centres is high (approximately 40%).29 
Thus, we believe that our cohort is representative of high-volume 
IBD centres in other parts of the world that apply early aggressive 
treatment and tight monitoring strategy, and after validation by 
an independent cohort from another geographic region the results 
may be generalized to this setting. Finally, the decision to start AZA 
and anti-TNFs was uniform and the IBD specialists at the centre 
followed the European and Hungarian guidelines and prescription 
regulations.
In summary, our prediction models identified significant differ-
ences in the probability of developing advanced disease in the short 
and intermediate course of CD. The referral risk matrix model included 
ASCA IgA and/or IgG, disease location and the need for early AZA use. 
Markers identified in this referral cohort were different from those pre-
viously published in the population-based cohort, suggesting that differ-
ent prediction models should be used for patients in the referral setting.
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